

AD _____

Award Number: W81XWH-12-1-0252

TITLE: Metal Occupancy of Zinc Finger Motifs as Determinants for Zn²⁺-Mediated Chemosensitization of Prostate Cancer Cells

PRINCIPAL INVESTIGATOR: William H. Gmeiner

CONTRACTING ORGANIZATION: Wake Forest University Health Sciences
Winston-Salem, NC 27157

REPORT DATE: December 2013

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE December 2013		2. REPORT TYPE Final		3. DATES COVERED 30 September 2012-29 September 2013	
4. TITLE AND SUBTITLE Metal Occupancy of Zinc Finger Motifs as Determinants for Zn ²⁺ -Mediated Chemosensitization of Prostate Cancer Cells				5a. CONTRACT NUMBER W81XWH-12-1-0252	
				5b. GRANT NUMBER W81XWH-12-1-0252	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) William H. Gmeiner E-Mail: bgmeiner@wakehealth.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Wake Forest University Health Sciences Winston-Salem, NC 27157				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this project is to determine how changes in levels of Zn ²⁺ affect the occupancy of proteins that include Zn ²⁺ finger motifs and how in turn Zn ²⁺ occupancy affects the function of prostate cancer cells and in particular response to chemotherapy. Our findings show that prostate cancer cells are highly sensitive to perturbations in Zn ²⁺ concentration with both increases and decreases of Zn ²⁺ causing cytotoxicity and increasing sensitivity to chemotherapy. Our studies showed that the effects of exogenous Zn ²⁺ on prostate cancer viability were reversible and that cells adapted to changes in Zn ²⁺ levels. In contrast, Zn ²⁺ chelation was irreversible and led to apoptosis. For the chemotherapy drug-candidate F10 Zn ²⁺ chelation was synergistic and has maximal effect when administered more than 24 h after treatment. A novel finding was that the serine protease Omi/HtrA2 enhanced F10-induced apoptosis in a Zn ²⁺ -dependent manner. Treatment with F10 induced p53-responsive genes p21 and Bax in a Zn ²⁺ -dependent manner. Extensive molecular dynamics simulations were undertaken on the Zn ²⁺ -finger peptide from NEMO, a component of the NF-κB responsive pathway. These computational experiments revealed the free energy for Zn ²⁺ dissociation from this peptide was ~2.5 kcal/mol. These experimental and computational studies will be pursued in future grant applications to develop a comprehensive understanding of the effects of Zn ²⁺ levels on the response of prostate cancer cells to chemotherapy.					
15. SUBJECT TERMS Prostate cancer, Zn ²⁺ , metal-protein interactions, structural biology					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	41	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	3
Body.....	3 - 7
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusion.....	8
References.....	9
Appendices.....	10 - 41

INTRODUCTION: The project “Metal Occupancy of Zinc Finger Motifs as Determinants for Zn²⁺-Mediated Chemosensitization of Prostate Cancer Cells” provides information on the extent that specific types of Zn²⁺-binding motifs are perturbed in prostate cancer cells in response to treatment with exogenous Zn²⁺ or chelators of Zn²⁺. The project is collaborative and is directed overall by Dr. Gmeiner in the Department of Cancer Biology at Wake Forest School of Medicine in collaboration with Dr. Salsbury in the Department of Physics at Wake Forest University. Dr. Gmeiner’s laboratory is performing cell-based assays evaluating the effects of exogenous Zn²⁺ as well as chelation of Zn²⁺ on prostate cancer cell viability and induction of apoptosis. Dr. Salsbury’s laboratory is performing computational studies investigating the stability of interactions between Zn²⁺-binding motifs in proteins and Zn²⁺ ions. This project seeks to identify the structure/function relationships in Zn²⁺-binding proteins that are responsible for the anti-tumor properties of Zn²⁺ and Zn²⁺-chelators. We expect the work completed to date to result in at least two publications the first of which is included in draft form (Gmeiner, et al.; **appendix #1**) and the second as a report summary (Godwin et al., 2013; **appendix #2**). This project has contributed to two new letters of intent (LOI) to the DoD PCRP – one to the Idea Award mechanism “Zn²⁺ Modulation for Treatment of Advanced Prostate Cancer” (Gmeiner PI) and the second to the Synergistic Idea award mechanism “Omi/HtrA2 as a Novel Target for Prostate Cancer Treatment” (Gmeiner & Salsbury co-PI’s). The Idea award LOI was invited for a full proposal and is under review.

BODY:

Aim 1: Determine to what extent Zn²⁺ increases chemotherapy-induced apoptosis in LNCaP and C4-2 cells in part by prolonging the half-life of p53 and increasing the levels of p53-induced pro-apoptotic target genes including Bax and PUMA.

Task 1A: Quantify intracellular Zn²⁺ levels in LNCaP, C4-2, and PC3 cells cultured under low, moderate, and high Zn²⁺ conditions using Fluo-Zn with fluorescence detection.

We developed fluorescence-based assays using 96 well plates and also used confocal microscopy to measure relative levels of intracellular Zn²⁺ and changes in intracellular Zn²⁺ concentrations in PC3 and C4-2 prostate cancer cells in response to treatment with either exogenous Zn²⁺ or Zn²⁺-chelators.

These studies are included in the manuscript in preparation (**Appendix #1**; Figure 2; references 1-7) as well as in Figure 1.




Figure 1: Confocal microscopy analysis of intracellular Zn²⁺ levels in C4-2 cells measured using Zinquin in cells treated with 6 micromolar Zn²⁺-pyrithione (ZnP). Fluorescence significantly above background is observed. For quantification and statistical analysis see appendix #1.

Task 1B: Evaluate apoptosis induction in LNCaP and C4-2 cells (both wt-p53) and PC3 (p53-null) cells following treatment with docetaxel using a caspase-glo 3/7 assay kit. Cells will be grown under low, moderate, and high Zn²⁺ conditions. (months 1-2).

We have completed these studies in PC3 and C4-2 cells using the novel fluoropyrimidine chemotherapy drug-candidate F10 as the chemotherapy agent. A summary of these studies is included in the manuscript in preparation (**Appendix #1**; Figure 4) and data for F10 in combination with the Zn²⁺-chelator TPEN is included in Figure 2. Our studies demonstrated that both exogenous Zn²⁺ and Zn²⁺-chelation is cytotoxic to prostate cancer cells and that Zn²⁺-chelation was highly effective at increasing the efficacy of chemotherapy.




Figure 2. Effects of decreasing Zn²⁺ levels in C4-2 prostate cancer cells using the chelator TPEN in combination with the chemotherapy drug-candidate F10. Effects on cell viability are shown in the upper panel and effects on caspase activation and induction of apoptosis are shown in the lower panel.

The substantial enhancement in apoptosis induction in prostate cancer cells in response to Zn²⁺-chelation with TPEN in combination with chemotherapy resulted in our developing a new project “Zn²⁺ Modulation for Treatment of Advanced Prostate Cancer”. We submitted a letter of intent (LOI) for the PCRP Idea mechanism and were invited to submit a full application that is currently under review.

Task 1C: Evaluate stabilization of p53 in LNCaP and C4-2 cells cultured under low-, moderate-, or high Zn²⁺ conditions in response to treatment with docetaxel.

For these studies we have focused mainly on evaluating expression of p53-target genes rather than levels of p53 itself as these endpoints are most relevant for induction of apoptosis (see Task 1D).

Task 1D: Evaluate expression of p53 target genes (e.g. PUMA, Bax, Mdm2) in LNCaP and C4-2 cells under low, moderate, and high Zn²⁺ conditions in response to treatment with docetaxel.

We have completed studies evaluating how modulation of intracellular Zn²⁺ levels using the Zn²⁺-chelator TPEN affects expression of p53 target genes including Bax and PUMA in C4-2 prostate cancer cells. A representative Western blot is included in Figure 3.




Figure 3. Representative Western blot evaluating expression of two p53-responsive genes: p21 (left) and Bax (right) in response to treatment of C4-2 cells with lane 1: no treatment; lane 2 F10; lane 3 TPEN; lane 4 F10+TPEN; lane 5 inhibitor of Omi HtrA2; lane 6 F10+TPEN+Omi. The pro-apoptotic p53 gene Bax was notably upregulated in response to treatment with chemotherapy in combination with Zn²⁺-chelation.

An interesting and unexpected finding in these studies was that inhibition of the serine protease Omi/HtrA2 enhanced chemotherapy-induced apoptosis in prostate cancer cells in a Zn²⁺-dependent manner. The rationale for why we initiated investigation of Omi/HtrA2 as a mediator of Zn²⁺-effects in prostate cancer cells is described in the introduction to the manuscript in preparation (**Appendix #1**). These findings served as the basis for a new Synergistic Idea application to the DoD PCRP program that was not selected for advancement although we think this is a highly significant finding and plan to pursue it as a topic for future grant submission.

Aim 2: Determine to what extent the Zn²⁺-finger from p53 is in apo-form in prostate cancer cells and evaluate changes in the apo/holo ratio for Zn²⁺-finger peptides upon growth under low-, moderate-, or high-Zn²⁺ conditions.

Task 2A: Immunoprecipitate p53 from LNCaP cells treated with docetaxel cultured under low-, moderate-, or high-Zn²⁺ conditions and provide the immunoprecipitated protein to Dr. Javier Seravalli for ICP-MS analysis.

We met with Dr. C. Furdai to discuss immunoprecipitation procedures and made plans to initiate these studies however successful implantation requires identifying conditions in which intracellular Zn²⁺ levels perturb the biological activity of p53. These studies were undertaken as part of specific aim 1 and we now have a firm understanding of how Zn²⁺ perturbs the biological activity of p53 and p53-responsive genes however the project terminated before we could undertake the immunoprecipitation studies.

Task 2B: Culture LCaP cells under low-, moderate-, or high-Zn²⁺ conditions with Zn²⁺ enriched in ⁶⁵Zn and determine the amount of Zn²⁺ in immunoprecipitated p53 by gamma counting.

We have not yet undertaken studies with ⁶⁵Zn.

Aim 3: Evaluate the extent to which the apo-form for Zn²⁺-finger motifs in p53 and Mdm2 differ in structure and stability relative to the metallated structure.

Task 3A: Evaluate the conformational dynamics of apo- and holo-forms of p53 and Mdm2.

Milestones/deliverables
for Task3A:

- i) Have 16 20ns or longer simulations (four for each of two proteins in each of two states)
- ii) Have detailed comparisons of apo- and holo-forms for each protein.




Figure 4. Structure of the Zn²⁺ finger from the protein NEMO with Zn²⁺ bound. Extensive MD simulation were run on this structure in the presence and absence of Zn²⁺ and energetics of Zn²⁺ binding were evaluated computationally.

We have completed multiple molecular dynamics simulations for the Zn²⁺ finger of NEMO, a protein important for transmitting signals of DNA damage from the nucleus to the cytoplasm (reference 8) and modulating the initiation of apoptosis. A summary of the MD simulations is included as Appendix #2 and we are working on preparing a manuscript based on our results. We see distinct difference in structure and energy for the apo- and holo-forms of this protein.

Task 3B: Evaluate the conformational free-energy changes that occur upon zinc binding.

Milestones/deliverables for Task 3B:

i) Have specific predictions for free-energy changes that occur due to the binding of zinc.

We have completed these studies and performed preliminary analyses. These studies indicate the free energy for Zn²⁺ binding is ~1.5 kcal/mol. A summary of these results is included as Appendix #2.

KEY RESEARCH ACCOMPLISHMENTS:

- We developed fluorescence assays for evaluating changes in intracellular Zn²⁺ in prostate cancer cells in response to treatment with Zn²⁺ and Zn²⁺ chelators
- We showed that the effects of chemotherapy are modulated both by exogenous Zn²⁺ and especially Zn²⁺ chelation (appendix #1)
- We showed increased expression of p53-responsive pro-apoptotic genes in response to Zn²⁺-chelation in combination with chemotherapy.
- We identified Omi/HtrA2 inhibition as a new strategy for prostate cancer treatment and enhancing the effectiveness of chemotherapy for prostate cancer treatment.
- We demonstrated that Zn²⁺ binding alters the stability of NEMO and calculated the energetic for this interaction. (appendix #2)

REPORTABLE OUTCOMES:

Manuscript in Preparation: Gmeiner, W.H., Boyacioglu, O., Jennings-Gee, J. “The Cytotoxic and Pro-Apoptotic Activities of the Novel Fluoropyrimidine F10 Towards Prostate Cancer Cells are Enhanced by Zn²⁺-Chelation and Inhibiting the Serine Protease Omi/HtrA2” In Preparation (appendix #1).

Manuscript in Preparation: Godwin, R. and Salsbury Jr., F. “NEMO Molecular Dynamics Simulations – effects of Zn²⁺ binding In Preparation (appendix #2).

Idea Award 2013 grant application: “Zn²⁺ Modulation for Treatment of Advanced Prostate Cancer” (Gmeiner PI)

Letter of intent for Synergistic Idea award mechanism “Omi/HtrA2 as a Novel Target for Prostate Cancer Treatment” (Gmeiner & Salsbury co-PIs)

CONCLUSION:

Prostate cancer cells tightly regulate Zn²⁺ levels and although this level is maintained at a much lower level in prostate cancer cells relative to normal prostate these cells are highly stressed by Zn²⁺ chelation and also by treatment with exogenous Zn²⁺. The combination of Zn²⁺ chelation and chemotherapy may be a highly effective strategy for prostate cancer treatment. The serine protease Omi/HtrA2 is newly identified as a Zn²⁺-responsive mediator of survival/apoptosis in prostate cancer cells. The combination of computational and experimental studies holds great promise for understanding the molecular interactions responsible for the response of prostate cancer cells to modulation of Zn²⁺ in combination with chemotherapy.

REFERENCES

1. Berlin, J.D., K.J. Propert, D. Trump, G. Wilding, G. Hudes, J. Glick, P. Burch, A. Keller, and P. Loehrer, *5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889)*. Am J Clin Oncol, 1998. **21**(2): p. 171-6.
2. Huan, S.D., S.E. Aitken, and D.J. Stewart, *A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer*. Ann Oncol, 1995. **6**(8): p. 836-7.
3. Morant, R., J. Bernhard, D. Dietrich, S. Gillessen, M. Bonomo, M. Borner, J. Bauer, T. Cerny, C. Rochlitz, M. Wernli, A. Gschwend, S. Hanselmann, F. Hering, and H.P. Schmid, *Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial*. Br J Cancer, 2004. **90**(7): p. 1312-7.
4. Zuo, J., S.M. Schmitt, Z. Zhang, J. Prakash, Y. Fan, C. Bi, J.J. Kodanko, and Q.P. Dou, *Novel Polypyridyl chelators deplete cellular zinc and destabilize the X-linked inhibitor of apoptosis protein (XIAP) prior to induction of apoptosis in human prostate and breast cancer cells*. J Cell Biochem, 2012. **113**(8): p. 2567-75.
5. Martins, L.M., I. Iaccarino, T. Tenev, S. Gschmeissner, N.F. Totty, N.R. Lemoine, J. Savopoulos, C.W. Gray, C.L. Creasy, C. Dingwall, and J. Downward, *The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif*. J Biol Chem, 2002. **277**(1): p. 439-44.
6. Vande Walle, L., M. Lamkanfi, and P. Vandenabeele, *The mitochondrial serine protease HtrA2/Omi: an overview*. Cell Death Differ, 2008. **15**(3): p. 453-60.
7. Liu, H.R., E. Gao, A. Hu, L. Tao, Y. Qu, P. Most, W.J. Koch, T.A. Christopher, B.L. Lopez, E.S. Alnemri, A.S. Zervos, and X.L. Ma, *Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion*. Circulation, 2005. **111**(1): p. 90-6.
8. McCool, KW and Miyamoto S DNA damage-dependent NF-kB activation: NEMO turns nuclear signaling inside out. Immunological Reviews 246: 311-326. 2012

APPENDIX:

Gmeiner, W.H., Boyacioglu, O., Jennings-Gee, J. “The Cytotoxic and Pro-Apoptotic Activities of the Novel Fluoropyrimidine F10 Towards Prostate Cancer Cells are Enhanced by Zn²⁺-Chelation and Inhibiting the Serine Protease Omi/HtrA2” In Preparation (appendix #1).

Godwin, R. and Salsbury Jr., F. “NEMO Molecular Dynamics Simulations – effects of Zn²⁺ binding In Preparation (appendix #2).

Appendix # 1

In Preparation December 2013

The Cytotoxic and Pro-Apoptotic Activities of the Novel Fluoropyrimidine F10 Towards Prostate Cancer Cells are Enhanced by Zn²⁺-Chelation and Inhibiting the Serine Protease Omi/HtrA2

William H. Gmeiner^{1,2*}, Olcay Boyacioglu¹, Jamie Jennings-Gee¹

¹Department of Cancer Biology and Comprehensive Cancer Center at Wake Forest School of Medicine, Winston-Salem, NC 27157

* Address correspondence to this author:

Phone: (336) 716-6216

Fax: (336) 716-0255

bgmeiner@wakehealth.edu

Grant sponsor: DOD CDMRP; NIH-NCI CA

BACKGROUND. Intracellular Zn²⁺ levels decrease during prostate cancer progression and agents that modulate intracellular Zn²⁺ are cytotoxic to prostate cancer cells by an incompletely described mechanism. F10 is a new polymeric fluoropyrimidine drug-candidate that displays strong activity with minimal systemic toxicity in pre-clinical models of prostate cancer and other malignancies. The effects of exogenous Zn²⁺ or Zn²⁺ chelation for enhancing F10 cytotoxicity are investigated as is the role of Omi/HtrA2, a serine protease that promotes apoptosis in response to cellular stress.

METHODS. To test the hypothesis that the pro-apoptotic effects of F10 could be enhanced by modulating intracellular Zn²⁺ we investigated cell-permeable and cell-impermeable Zn²⁺ chelators and exogenous Zn²⁺ and evaluated cell viability and apoptosis in cellular models of castration-resistant prostate cancer (CRPC; PC3, C4-2). The role of Omi/HtrA2 for modulating apoptosis was evaluated by pharmacological inhibition and Western blotting.

RESULTS. Exogenous Zn²⁺ initially reduced prostate cancer cell viability but these effects were transitory and were ineffective at enhancing F10 cytotoxicity. The cell-permeable Zn²⁺-chelator TPEN induced apoptosis in prostate cancer cells and enhanced the pro-apoptotic effects of F10. The pro-apoptotic effects of Zn²⁺-chelation in combination with F10 treatment were enhanced by inhibiting Omi/HtrA2 implicating this serine protease as a novel target for prostate cancer treatment.

CONCLUSIONS. Zn²⁺-chelation enhances the pro-apoptotic effects of F10 and may be useful for enhancing the effectiveness of F10 for treatment of advanced prostate cancer. The serine protease Omi/HtrA2 modulates Zn²⁺-dependent apoptosis in prostate cancer cells and represents a new target for treatment of CRPC.

KEY WORDS: Zn²⁺, castration-resistant prostate cancer, F10, fluoropyrimidine, Omi/HtrA2

INTRODUCTION. The relationship between Zn^{2+} and prostate cancer incidence, response to chemotherapy, and recurrence is complex. In general, prostate cancer cells have low intracellular Zn^{2+} levels (Costello and Franklin, 2011) although Zn^{2+} levels may vary during disease progression (Banas et al., 2010). Further, increased dietary Zn^{2+} is associated with prostate cancer survival (Epstein et al., 2011) although chronic zinc oversupply may enhance risk of prostate cancer (Leitzman et al., 2003). Either low or high dietary zinc increased tumor burden in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer. Low levels of Zn^{2+} and Fe^{2+} correlated with disease recurrence in prostate cancer patients (Sarafanov et al., 2011). The importance of Zn^{2+} levels for prostate cancer progression has resulted in development of imaging modalities to sense Zn^{2+} levels as well as therapeutic approaches to modulate Zn^{2+} to enhance chemotherapy. The sensitivity of prostate cancer cells to both exogenous Zn^{2+} and Zn^{2+} chelation suggests Zn^{2+} levels are tightly regulated and not simply minimized in prostate cancer cells.

The apparently complex relationship between Zn^{2+} levels and prostate cancer incidence and recurrence has resulted in studies to modulate intracellular levels of Zn^{2+} for therapeutic benefit. Zn^{2+} is transported into cells by the SLC39 (Zip-family) members and is transported out of cells by SLC30 (ZnT) zinc transporters (Franz et al., 2013). Decreased expression of Zip-family members is characteristic of prostate cancer and as a consequence treatment of PCa cells with Zn^{2+} salts (e.g. ZnSO_4) may have minimal effect on intracellular Zn^{2+} necessitating Zn^{2+} -delivery with a cell-permeable chelate, such as pyridithione (ZnPy). Several studies have, however, reported that Zn^{2+} salts can be cytotoxic to prostate cancer cells. For example, zinc acetate was cytotoxic to PC3, LNCaP, and DU145 cells and direct intratumoral injection decreased tumor growth. (Shah et al., 2009).

Other studies however report that while zinc salts are readily taken up and retained by myeloid progenitor cells and protect these cells from the pro-apoptotic effects of docetaxel chemotherapy similar treatment does not result in increased Zn^{2+} levels in prostate cancer cells or protect these cells from docetaxel-induced apoptosis (Makhov et al., 2011). In contrast to Zn^{2+} salts, treatment with ZnPy increased Zn^{2+} levels in prostate cancer cells and was cytotoxic to DU145, PC3, and LNCaP cells (Kriedt et al., 2010) and enhanced PTX- and $TNF\alpha$ -mediated apoptosis in PC3 cells (Uzzo et al., 2006). Thus, the effects of Zn^{2+} on prostate cancer cells depends on the cell permeability of administered Zn^{2+} as well as on the chemotherapy co-administered.

The present studies focus on modulating intracellular levels of Zn^{2+} in prostate cancer cells to enhance the effectiveness of chemotherapy with F10, a novel polymeric fluoropyrimidine that has shown promising activity in pre-clinical models of highly lethal malignancies including acute myeloid leukemia (AML) and glioblastoma (GBM). Our laboratory is interested in the potential of F10 for improved treatment of prostate cancer based upon results from the NCI 60 cell line screen indicating that cellular models of castration-resistant prostate cancer (CRPC; e.g. PC3, DU145) were highly sensitive to F10 with GI_{50} values in the nanomolar range. F10 displays large advantages relative to current chemotherapy and PC3 cells were more than 600-fold more sensitive to F10 relative to the conventional fluoropyrimidine drug 5-fluorouracil (5FU). These results suggest that F10 might be useful for treating CRPC despite clinical studies with 5FU and capecitabine demonstrating these drugs lack efficacy for prostate cancer treatment [1-3]. We report herein investigations of treatment effects in cellular models of CRPC (C4-2 and PC3) with exogenous Zn^{2+} as well as with Zn^{2+} -chelators both as single agents and in combination with F10. The cell

permeable Zn²⁺ chelator TPEN displays strong single agent activity and enhanced the pro-apoptotic effects of F10 towards PC3 and C4-2 cells demonstrating the potential for Zn²⁺-chelation to be used to enhance F10 efficacy for CRPC treatment.

The molecular targets affected by Zn²⁺-treatment in prostate cancer and other cells have been partly elucidated and include mediators of apoptosis such as caspase 3 and the caspase 3 substrate X-linked inhibitor of apoptosis (XIAP). Zn²⁺ inhibits the activity of caspase 3 (Perry et al., 1997) and cell-permeable Zn²⁺ chelators including TPEN (Chimienti et al., 2001) and PAC-1 (Peterson et al., 2009) induce apoptosis through increased caspase 3 activation. Zinc depletion also results in cleavage of XIAP prior to induction of apoptosis in prostate cancer cells in a caspase-independent as well as proteasome-independent manner [4]. The Zn²⁺-dependent cleavage of XIAP is selective and neither cIAP1 nor cIAP2 are similarly affected by Zn²⁺ chelation. Zn²⁺-dependent XIAP cleavage is inhibited by Pefabloc implicating a serine protease in mediating these effects. A potential candidate Ser protease for Zn²⁺-dependent XIAP degradation is Omi/HtrA2. Omi/HtrA2 undergoes auto-catalysis to release a form that has homology to Smac/DIABLO[5]. This cleaved product has pro-apoptotic properties resulting from sequestering XIAP, and thus indirectly activates caspase 3[6]. Omi/HtrA2 is located in the mitochondria, however upon pro-apoptotic stimulation processed Omi/HtrA2 translocates into the cytosol and binds XIAP. Although Omi/HtrA2 is known to be important for promoting apoptosis in response to cellular stress[7], it has not been previously reported to contribute to apoptosis in PCa cells. We report that Omi/HtrA2 inhibition has single agent activity and induces apoptosis in prostate cancer cells. Our studies also show that inhibiting Omi/HtrA2 enhances F10-induced apoptosis (and synergizes) with F10 towards CRPC cells. These studies demonstrate Omi/HtrA2 is a novel target for prostate cancer treatment.

Materials and Method

Cell Maintenance: C4-2 cell line was a gift from Dr. Elizabeth M. Wilson (UNC, Chapel Hill, NC). PC3 cells were purchased from cell and viral vector core laboratory at Wake Forest School of Medicine. All cells were maintained with RPMI 1640 (Gibco, Grand island, NY) with 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA). All cells were kept at 5% CO₂ at 37 °C.

Zn²⁺ and Drug Treatment. F10 was synthesized as previously described. All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless indicated otherwise.

Zinc cytotoxicity in the form of ZnP, NaP, and ZnSO₄: PC3 and C4-2 cells were seeded at a density of 3,000 cells/well in 96-well plates and incubated at 37 °C under 5% CO₂. Next day, the cells were treated with ZnP, NaP, or ZnSO₄ for 72 h. Live cell counts were measured indirectly by measuring the ATP amounts using CellTiter-Glo® luminescent cell viability assay (Promega, Madison, WI) according to the manufacturer's protocol.

Co-treatment with FdUMP[10] and ZnP: PC3 and C4-2 cells were seeded at a density of 3,000 cells/well in 96-well plates and incubated at 37 °C under 5% CO₂. Next day, the cells were treated with FdUMP and ZnP for 48-72 h. Total ATP levels were measured at the end of the treatment time using CellTiter-Glo® luminescent cell viability assay.

Intracellular Zinc Measurements: PC3 and C4-2 cells were seeded at a density of 3,000 cells/well in 96-well plates and incubated at 37 °C under 5% CO₂. Four days later, the media was removed and cells were incubated under minimal light for 30 min at 37 °C with 1

μM of FluoZin™-3 AM (Molecular Probes, Eugene, OR) in phosphate-free, Hepes-buffered Hanks' balanced salt solution (HHBSS) (KCl 0.4 g, NaHCO_3 0.35 g, CaCl_2 0.14 g, $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ 0.1 g, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.1 g, NaCl 8 g, D-glucose 1 g, Hepes 5.2 g for 1 liter volume) since phosphate precipitates Zn^{2+} in solution. After 30 min, the buffer with FluoZin-3 AM was discarded and the cells were incubated with ZnP in HHBSS for 1 h at 37 °C followed by twice wash with HHBSS. Fluorescence emitted by the FluoZin-3 AM that bound Zn^{2+} and trapped inside the cells was measured at using (the plate reader in Debinski Lab) excitation/emission wavelengths of 485/520 nm.

Microscopy

Western blots

Statistical Analysis

RESULTS

Cytotoxicity of Exogenous Zn^{2+} and Zn^{2+} -Chelation. The effects of exogenous Zn^{2+} or of Zn^{2+} chelation on the viability of prostate cancer cells were investigated using PC3 and

C4-2 cells treated with either zinc sulfate or with the cell permeable zinc chelator pyrithione as either the sodium or zinc complex. Alternatively, prostate cancer cells were treated with the cell impermeable Zn^{2+} chelator DTPA to decrease Zn^{2+} concentrations in culture media and indirectly decrease intracellular Zn^{2+} . The results revealed a marked time-dependence to the effects of both exogenous Zn^{2+} and its chelation on prostate cancer cell viability (**Figure 1**). Treatment with zinc sulfate initially decreased cell viability, particularly for C4-2 cells, however 72 h of continuous treatment with elevated exogenous Zn^{2+} resulted in no significant change to the viability of PC3 cells and only a moderate (~20%) decrease in the viability of C4-2 cells consistent with cellular adaptation to increased Zn^{2+} in culture medium. The effects of zinc salts on cell viability were independent of the counterion with zinc chloride as effective as zinc sulfate demonstrating the specificity of cell viability effects on Zn^{2+} levels.

Pyrithione is a pyridine N-oxide that forms a 2:1 complex with Zn^{2+} that is cell permeable and widely used for studies evaluating the effects of increased intracellular Zn^{2+} on cell function independent of cell transport. Our studies show that sodium pyrithione that cannot deliver exogenous Zn^{2+} is cytotoxic to both C4-2 and PC3 cells in a time-dependent manner consistent with pyrithione affecting cell viability independent of Zn^{2+} delivery. Pyrithione cytotoxicity is however enhanced when combined with exogenous Zn^{2+} - conditions that enhance cell-uptake of Zn^{2+} independent of Zn^{2+} transporter function (**Figure 1**). The combination of pyrithione and Zn^{2+} shows reduced effects on cell viability at later timepoints as was observed for Zn^{2+} -only treatment consistent with prostate cancer cells adapting to increased intracellular Zn^{2+} at timepoints longer than 24 h. The results demonstrate that pyrithione affects prostate cancer viability independent of Zn^{2+} transport while the zinc complex exerts Zn^{2+} specific effects on cell viability.

While exogenous Zn^{2+} decreases the viability of prostate cancer cells, Zn^{2+} chelation with the cell impermeable Zn^{2+} chelator DTPA also decreases viability consistent with cellular homeostasis requiring tight regulation of intracellular Zn^{2+} that is dependent on the concentration of free Zn^{2+} in culture medium. The reduction in prostate cancer cell viability due to chelating Zn^{2+} in culture medium is slower than effects resulting from exogenous Zn^{2+} treatment with significant reduction in viability at 72 h but not at 24 h of treatment (**Figure 1**). The cytotoxic effects of DTPA-treatment were completely reversed by co-treatment with zinc sulfate consistent with DTPA cytotoxicity resulting from Zn^{2+} chelation. Sodium pyrithione enhanced the effects of DTPA and this enhancement was reversed by zinc sulfate consistent with pyrithione cytotoxicity being Zn^{2+} -dependent.

Cell Imaging of Intracellular Zn^{2+} . The cytotoxic effects of exogenous Zn^{2+} were investigated using the cell-permeable Zn^{2+} -sensitive fluorescent dyes Zinquin and FluoZin-3 (**Figure 2**). Treatment of both PC3 and C4-2 cells with ZnPy resulted in concentration-dependent increases in FluoZin fluorescence in cells pre-treated with FluoZin consistent with intracellular transport of Zn^{2+} being responsible for the cytotoxicity of ZnPy. The sub-cellular distribution of fluorescence resulting from FluoZin and Zinquin treatment was distinct although both fluorophores displayed strong concentration-dependent fluorescence that was responsive to ZnPy treatment consistent with the observed fluorescence being correlated with Zn^{2+} uptake into prostate cancer cells. Zinquin fluorescence was punctate consistent with sequestration into endosomes, lysosomes or other organelles while FluoZin fluorescence was diffuse consistent with predominantly cytoplasmic distribution. Intriguingly, treatment with the cell-permeable Zn^{2+} chelator TPEN, which is also cytotoxic to prostate cancer cells, also caused a much more modest yet reproducible increase in

fluorescence monitored by either Zinquin and FluoZin pre-treatment consistent with perturbation of Zn^{2+} levels. While the origin of Zn^{2+} -dependent fluorescence by Zinquin and FluoZin remains under investigation and apparently involves interaction of the fluorophores with Zn^{2+} -binding proteins rather than with an aqueous free- Zn^{2+} pool in cells, the results are consistent with ZnPy cytotoxicity being mediated through increased intracellular Zn^{2+} levels.

ZnPy Combination Effects with Chemotherapy. Our studies demonstrated ZnPy decreased cell viability via increased intracellular Zn^{2+} . To determine to what extent ZnPy treatment could be used in combination with chemotherapy we investigated co-treatment of ZnPy with F10, a novel polymer of 5-fluoro-2'-deoxyuridine-5'-O-monophosphate, the active metabolite of fluoropyrimidine chemotherapy that displays strong anti-cancer activity and minimal systemic toxicity in pre-clinical models of AML and GBM and that in previous studies demonstrated strong cytotoxicity towards prostate cancer cells. F10 reduced the viability of both PC3 and C4-2 cells with IC50 values in the nanomolar range (**Figure 3**). PC3 cells were markedly more sensitive to the effects of ZnPy relative to C4-2 cells although the IC50 for ZnPy in both cell lines exceeded 100 micromolar. Further, at concentrations of ZnPy that induced at least 50% reduction in viability for either cell line the effects of ZnPy treatment were independent of F10 concentration consistent with higher concentrations of ZnPy interfering in F10 cytotoxicity. Interestingly, while either F10 or ZnPy reduced the viability of prostate cancer cells only F10 induced apoptosis and ZnPy at higher concentrations inhibited F10-induced apoptosis. ZnPy did decrease levels of full-length Caspase 3 however the cleaved fragment p16 was not detected and caspase 3/7 glo assays did not indicate the occurrence of end-stage apoptosis. Both ZnPy and F10 resulted in decreased levels of pAkt consistent with induction of changes in cellular signaling that

disfavor cell proliferation. As F10 cytotoxicity is highly dependent on cell proliferation, the decreased levels of pAkt that occur upon ZnPy treatment may reduce DNA replication and cell division providing the basis for minimizing the cytotoxic and apoptotic effects of F10.

Intracellular Zinc Chelation is Cytotoxic and Enhances F10-induced Apoptosis: In contrast to DTPA that is cell impermeable, the Zn²⁺ chelator TPEN is readily internalized by prostate cancer cells (**Figure 4**). Our studies demonstrated that treatment with TPEN reduced the viability of prostate cancer cells and that the effects of TPEN were more rapid than occurred via chelation of Zn²⁺ in culture medium with DTPA. TPEN treatment also significantly reduced FluoZin fluorescence in C4-2 cells, consistent with effects on cell viability being Zn²⁺-mediated. Further, the effects of TPEN treatment on cell viability were completely reversed by co-treatment with zinc sulfate as was reduction in FluoZin fluorescence. Co-treatment of PC3 and C4-2 cells with TPEN during the final six hours of F10 treatment resulted in significant reduction in cell viability and increased apoptosis. The combination of F10 and TPEN was synergistic (**Chris – can you check this and get a CI value?**) and the effects of TPEN were negated by co-treatment with Zn²⁺. Treatment with F10 and F10 + TPEN resulted in increased expression of p53-responsive pro-apoptotic genes p21 and Bax in C4-2 cells consistent with F10 inducing apoptotic death and Zn²⁺-chelation with TPEN stimulating execution of apoptosis.

We then sought to determine if the pro-apoptotic effects of Zn²⁺-chelation might be mediated by the serine protease Omi/HtrA2. Omi/HtrA2 undergoes autocatalysis to release a product that has homology to Smac/DIABLO and which has pro-apoptotic properties resulting from sequestering the anti-apoptotic protein XIAP. As the apoptotic effects of Zn²⁺-chelation are mediated via caspase 3 activation which in turn is inhibited by XIAP

Omi/HtrA2 activation may be expected to enhance apoptosis by sequestering XIAP. Changes in Omi/HtrA2 expression were evaluated by Western blot and the effects of Omi/HtrA2 inhibition for mitigating the apoptosis-stimulating effects of Zn²⁺-chelation in F10-treated cells were evaluated using the inhibitor UCF-101. Western blot revealed no change in the expression of Omi/HtrA2 under any conditions examined. Surprisingly, however, inhibiting Omi/HtrA2 enhanced the cytotoxic and pro-apoptotic effects of F10 and further enhanced the pro-apoptotic effects of Zn²⁺-chelation. These results reveal an anti-apoptotic role for Omi/HtrA2 in F10-treated cells and identify Omi/HtrA2 as a putative therapeutic target for treatment of prostate cancer.

DISCUSSION

Castration-resistant prostate cancer remains incurable with chemotherapy offering only a moderate survival advantage that is achieved with treatment regimens that compromise patient quality of life. Pre-clinical studies with the fluoropyrimidine polymer F10 have demonstrated this novel drug-candidate displays excellent anti-cancer activity in pre-clinical animal models of acute myeloid leukemia (AML) and glioblastoma, two highly lethal malignancies for which new treatment options are also urgently needed. Data from the NCI 60 cell line screen as well as from our laboratory have demonstrated that F10 is highly cytotoxic to prostate cancer cells with the present studies demonstrating F10 is cytotoxic to C4-2 and PC3 cells at nanomolar levels. The present studies have demonstrated that the cytotoxic effects of F10 towards prostate cancer cells can be enhanced by modulating

intracellular Zn²⁺ levels providing the basis for developing new therapeutic modalities that simultaneously deliver F10 and modulate Zn²⁺ for therapeutic benefit.

The progression of prostate cancer is paralleled by sequentially decreased levels of intracellular Zn²⁺ consistent with low levels of Zn²⁺ in prostate cancer cells presenting a survival advantage. Consistent with this interpretation prostate cancer cells in culture as well as in human malignant tissue express decreased levels of zinc transporters and increased levels of Zn²⁺ efflux pumps. Further, administering exogenous Zn²⁺ has been found to decrease prostate cancer cell viability and studies from our laboratory demonstrate that strategies to deliver Zn²⁺ enhance the cytotoxicity of chemotherapy under some conditions. The present studies demonstrate that treatment of prostate cancer cells with Zn²⁺ salts initially decreases cell viability, however these effects are transitory and cell recover full viability within 72 h. The cell permeable ionophore pyrithione reduces prostate cancer cell viability as the sodium complex and these effects are enhanced for the Zn²⁺ complex (Zn-Py). As with cell impermeable Zn²⁺-salts, the effects of Zn²⁺-Py are decreased at longer treatment times consistent with cellular adaptation to increased Zn²⁺. Further, Zn²⁺-Py is effective at enhancing the cytotoxicity of F10 only at low concentrations with higher concentration of Zn-Py that have substantial single-agent effects inhibiting F10 cytotoxicity. The finding that Zn-Py reduces pAkt levels is consistent with Zn-Py promoting cytostasis thus limiting the effectiveness of F10 which is proliferation dependent.

Although prostate cancer cells maintain Zn²⁺ levels at very low levels relative to normal prostate, further reduction in intracellular Zn²⁺ through Zn²⁺ chelation results in apoptosis. These observations are consistent with low levels of Zn²⁺ being important for maintaining a pro-survival balance in prostate cancer cells. Our studies show that both cell-impermeable

(e.g. DTPA) and cell-permeable (e.g. TPEN) Zn²⁺-chelators each reduce the viability of prostate cancer cells. The effects of DTPA are considerably slower than TPEN demonstrating that cell-permeable Zn²⁺ chelation has potential for rapid induction of apoptosis in prostate cancer cells. Further, the combination of F10 and TPEN is synergistic (CI = ?) demonstrating the potential for cell-permeable Zn²⁺ chelation to be used to enhance the efficacy of F10 chemotherapy. The mechanism by which Zn²⁺-chelation enhances F10-induced apoptosis is not known, however Zn²⁺ has been shown to form a specific complex with Cysxxx in caspase 3 that inhibits apoptosis. F10-induced apoptosis may be attenuated though Zn²⁺-complexation of caspase 3 with Zn²⁺-chelation overcoming this attenuation.

The mechanism by which Zn²⁺-chelation tips the survival/apoptosis balance to apoptosis in prostate cancer cells is not known. Previous studies demonstrated TEPN treatment resulted in selective depletion of the X-linked inhibitor of apoptosis (XIAP) and this degradation was prevented by the serine protease inhibitor Pefabloc. The present studies investigated a potential role for the serine protease Omi/HtrA2 in the Zn²⁺-dependent degradation of XIAP. Omi/HtrA2 undergoes auto-catalysis to release a form that has homology to Smac/DIABLO and that has pro-apoptotic properties resulting from sequestering XIAP. Omi/HtrA2 has also been shown to promote apoptosis in response to cellular stress. Surprisingly, our results implicate an anti-apoptotic role for Omi/HtrA2 with pharmacological inhibition markedly enhancing F10- and F10/TPEN-induced apoptosis. These results identify Omi/HtrA2 as a novel target for prostate cancer treatment with inhibitors of Omi/HtrA2 may have single agent activity as well as enhance the pro-apoptotic activities of chemotherapy towards prostate cancer cells.

CONCLUSION

Zn²⁺-chelation with cell permeable moieties represents a promising strategy for prostate cancer treatment that may also enhance the efficacy of chemotherapy. TEPN treatment enhances F10-induced apoptosis in PC3 and C4-2 cells demonstrating the potential for this combination therapy approach to be further evaluated in pre-clinical models of castration-resistant prostate cancer. In light of the low toxicity and strong anti-cancer activity of F10 in animal models of AML and GBM this combination is likely to be effective and well-tolerated for prostate cancer treatment. The serine protease Omi/HtrA2 contributes to prostate cancer cell survival and pharmacological inhibition of Omi/HtrA2 enhances the pro-apoptotic properties of F10 and F10/TPEN. These studies identify Omi/HtrA2 as a potential new target for prostate cancer treatment.

ACKNOWLEDGEMENT

REFERENCES

1. Berlin, J.D., K.J. Propert, D. Trump, G. Wilding, G. Hudes, J. Glick, P. Burch, A. Keller, and P. Loehrer, *5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889)*. Am J Clin Oncol, 1998. **21**(2): p. 171-6.
2. Huan, S.D., S.E. Aitken, and D.J. Stewart, *A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer*. Ann Oncol, 1995. **6**(8): p. 836-7.
3. Morant, R., J. Bernhard, D. Dietrich, S. Gillessen, M. Bonomo, M. Borner, J. Bauer, T. Cerny, C. Rochlitz, M. Wernli, A. Gschwend, S. Hanselmann, F. Hering, and H.P. Schmid, *Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial*. Br J Cancer, 2004. **90**(7): p. 1312-7.
4. Zuo, J., S.M. Schmitt, Z. Zhang, J. Prakash, Y. Fan, C. Bi, J.J. Kodanko, and Q.P. Dou, *Novel Polypyridyl chelators deplete cellular zinc and destabilize the X-linked inhibitor of apoptosis protein (XIAP) prior to induction of apoptosis in human prostate and breast cancer cells*. J Cell Biochem, 2012. **113**(8): p. 2567-75.
5. Martins, L.M., I. Iaccarino, T. Tenev, S. Gschmeissner, N.F. Totty, N.R. Lemoine, J. Savopoulos, C.W. Gray, C.L. Creasy, C. Dingwall, and J. Downward, *The serine*



- protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif.* J Biol Chem, 2002. **277**(1): p. 439-44.
6. Vande Walle, L., M. Lamkanfi, and P. Vandenabeele, *The mitochondrial serine protease HtrA2/Omi: an overview.* Cell Death Differ, 2008. **15**(3): p. 453-60.
 7. Liu, H.R., E. Gao, A. Hu, L. Tao, Y. Qu, P. Most, W.J. Koch, T.A. Christopher, B.L. Lopez, E.S. Alnemri, A.S. Zervos, and X.L. Ma, *Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion.* Circulation, 2005. **111**(1): p. 90-6.

Supporting Information.

Draft Figures

**The Cytotoxic and Pro-Apoptotic Activities of the Novel
Fluoropyrimidine F10 Towards
Prostate Cancer Cells are Enhanced by Zn²⁺-Chelation
and Inhibiting the Serine Protease Omi/HtrA2**

William H. Gmeiner, Olcay
Boyacioglu, Jamie Jennings-Gee



50 μ M DTPA		+			+	+		+
1.2 μ M NaP			+		+		+	+
50 μ M ZnSO ₄				+		+	+	+

Figure 1: Effect of treatment with the cell-impermeable Zn²⁺ chelator DTPA or cell permeable sodium pyrrithione w/wo Zn²⁺ for the indicated times in PC3 and C4-2 cells.








A

Figure 2 – Change in FluoZin fluorescence following treatment with Zn²⁺ pyrithione at the indicated concentrations. B – D confocal images of C4-2 cells following treatment with B – no treatment; C – 6 microM ZnPt Zinquin detection; D – 6 microM ZnPt FluoZin detection



6 μM TPEN		+	+	+	+	+	+	+
2 μM ZnSO ₄			after 0h		after 1h		after 2h	
6 μM ZnSO ₄				after 0h		after 1h		after 2h





6 μM TPEN		+	+			
ZnSO ₄			6 μM	2 μM	6 μM	10 μM

Figure 3 A,B effect of Zn²⁺ chelation with TPEN on PCa viability; C,D rescue of TPEN effects with Zn²⁺

Figure 4. Effects of combining TPEN treatment with F10 chemotherapy on Pca viability and apoptosis

PC3 (48h)

C4-2 (72 h)








Figure 5. Western blot showing effects of F10 (F) or ZnPy (Z) or both treatments on levels of caspase 3, phosphorylation of Akt, and total Akt.

A



B



C




Figure 6. Effects of treatment with TPEN +/- Zn²⁺ on A) FLuoZin fluorescence; B Cell viability; C – effects of TPEN during last six hours of 48 h F10 treatment on C4-2 cell viability and apoptosis

NEMO- All Atom Molecular Dynamics

Ryan Godwin
December 12, 2013

Submitted APS Abstract (11.15.13)

Conformational Analysis on structural perturbations of the zinc finger NEMO

Ryan Godwin & Freddie Salsbury

The NEMO (NF- κ B Essential Modulator) Zinc Finger protein (2jvx) is a functional Ubiquitin-binding domain, and plays a role in signaling pathways for immune/inflammatory responses, apoptosis, and oncogenesis [Cordier *et al.*, 2008]. Characterized by 3 cysteines and 1 histidine residue at the active site, the biologically occurring, bound zinc configuration is a stable structural motif. Perturbations of the zinc binding residues suggest conformational changes in the 423 atom protein characterized via analysis of all-atom molecular dynamics simulations. Structural perturbations include simulations with and without a zinc ion and with and without de-protonated cysteines, resulting in four distinct configurations. Simulations of various time scales show consistent results, yet the longest, GPU driven, microsecond runs show more drastic structural and dynamic fluctuations when compared to shorter duration time-scales. The last cysteine residue (26 of 28) and the helix on which it resides exhibit a secondary, locally unfolded conformation in addition to its normal bound conformation. Combined analytics elucidate how the presence of zinc and/or protonated cysteines impacts the dynamics and energetic fluctuations of NEMO.


Summary to Date

There are two main ideas to express, and this document will (try to) focus on the later. The first idea is that nano-scale simulations are insufficient when examining energetics of proteins in these sorts of all-atom MD simulations. Microseconds and longer are really needed to provide enough sampling to understand kinetic changes available to the system. The second idea is the primary results of the simulations to date and corresponding analysis of the 4 configurations of the NEMO, with the microsecond simulations the focus of the analysis. Additional investigations of zinc finger proteins are underway (3CLX simulations are almost complete, 1I3O, 1C9Q & 2QRA are on deck) and we're investigating the incorporation of TPEN molecule into zinc finger simulations.

Background Material

NEMO is a 28 residue, 432 atom protein that binds a zinc ion at the 6th, 9th, 22nd, and 26th residues. These binding residues are cysteine, cysteine, histidine, cysteine,

respectively as highlighted in the image below. There are 2 beta sheets and an alpha helix along with two hairpin turns each approximated by the cartoon below the amino acid sequence.



A depiction of the protein including the secondary structures, residues and bound zinc (green orb) is also shown in the figure.

We investigated four configurations of the protein, as described in the abstract and highlighted in the following table. The thermodynamic cycle, including the two physiologically pertinent configurations, in bold, is:

With Zinc	Without Zinc
CYN	CYN
With Zinc	Without Zinc
CYS	CYS


Simulations were recorded of various durations, and some sampling was gathered for the shorter scale simulations as highlighted in the following table

15 nanoseconds (300 ns sampling)
30 nanoseconds (300 ns sampling)
1 microsecond (1 mus sampling)

So let's move on to the more interesting stuff... data.

RMSF

RMSF values for all four configurations at each of the three time scales are all plotted below. The plots, from top to bottom are 15 ns, 30 ns, and 1 μ s. The black squares highlight some of the larger effects, especially at the termini of the protein, found in longer simulations.



Clustering

Clustering seems to be as much of an art at the moment as a science. A cutoff of 4 angstroms of heavy atoms and 50 bins were used for the clustering parameters clustering 10000 frames of the microsecond trajectory. This was the best 'middle ground' distance to help cluster the more difficult to cluster non-biologically relevant states without sacrificing too much at the nicely behaved, biologically relevant regime.

Clusters

Clustering analysis is used to compare relative populations of states across the four structural configurations.


See supplemental Pdf

Markov Rate Matrix


The Markov Rate matrix shows the probability from transitioning from one state (along the y-axis) to another (along the x-axis). These types of plots can highlight kinetic traps, a particular state that has a very low probability of leaving that once it is found. It also highlights kinetically isolated states, which might interact with only one or two other states.

The converging probabilities checks that the states are expected to be found within a reasonable number of steps given that they start populated and unpopulated. The x-axis represents the number of steps and the y-axis is the ratio of the probabilities of being in that state to the final state.


First looking at WZN CYN there are only 9 states given the structural stability and the large cutoff distance.




Now removing the zinc we'll look at the WoZN CYN case. There is definitely a higher order state (maybe 42) that is a kinetic trap. There is also a good deal of kinetic isolation in the middle states.



For the WZN CYS case, we have, again that the unclustered structures dominate and the low-lying states are rather kinetically isolated.



Finally, the other biologically relevant configuration has the following Markov chain.




We see that all of the probabilities converge within 50 steps, supporting the Markov plots.


Correlation

Native Contacts




Pairwise contacts are considered native when they occur more than 2/3 of the trajectory. In the heavy atom analysis uses a cutoff distance of 4 Angstroms, and interactions within **two** atoms along the backbone are omitted. This parameter might need to be changed in favor of removing more backbone interactions that can distort the native contact percentages.

These plots show the Free energy surface based on the probabilities of native contacts, compared to the biologically relevant bound zinc case. The y-axis should be Energy (kcal/mol). First, we have the No zinc deprotonated cysteines....I realize this is not consistent with the legend-don't trust the legend. Then the two cases with zinc, followed up by the other biologically relevant case. The well is shifted to a lower probability in all three cases, suggesting that the bound zinc motif is favorable.





This analysis is also interesting if we look at the other biologically relevant case of no Zinc and protonated cysteines.



Poisson Boltzmann Analysis

While this has yet to be analyzed for the microsecond sims, there are some results worth noting at the 15ns regime. ...

Local Unfolding

In the biologically bound zinc case (WZN-CYN) there is noticeable local unfolding characterized by motion of the last binding cysteine (residue 26 of 28). The working hypothesis here is that this local unfolding is part of a search mechanism for other binding moieties whether that be another zinc finger or possibly a TPEN molecule

For the No Zinc CYS case, we see much larger portions of the protein unfolding. Again see pdf slides for image details.

Supplemental

A great deal of the analysis presented in this document was analyzed using code developed to automate the analysis of molecular dynamics simulations. Currently, efforts are underway to automate the setting up and execution of the simulations with the larger aim to automate the whole process from generating the protein environment from a particular pdb (or set of input) through the analysis, and incorporating an iterative process where the code can setup and execute further simulations based on the analysis of the previous run. This project will take sometime, but could provide us theorists with a high-throughput, objective way of generating and analyzing lots and lots of data.